Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

72.69
+6.049.06%
Post-market: 72.02-0.6700-0.92%19:59 EDT
Volume:15.97M
Turnover:1.13B
Market Cap:13.12B
PE:-50.70
High:72.96
Open:65.60
Low:65.25
Close:66.65
52wk High:104.32
52wk Low:40.77
Shares:180.43M
Float Shares:115.00M
Volume Ratio:1.53
T/O Rate:13.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:29.48
PE(LYR):-51.55

Loading ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)

TIPRANKS
·
Jun 01

Tempus AI Launches Next-Generation Agentic AI Platform for Oncology Drug Development

MT Newswires Live
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01

Short Report: Tempus AI short interest at record high

TIPRANKS
·
Jun 01

Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push

Benzinga Earnings
·
May 31

Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs

TIPRANKS
·
May 31

Tempus AI announces introduction of Tempus Preview

TIPRANKS
·
May 31

Tempus AI CEO and Chairman Eric Lefkofsky reports sale of 166,250 common shares worth $7.76 million

Reuters
·
May 30

AI Application Software Shares Extended Gains. Palantir Up 10%; Salesforce And Rubrik Up 8%; Snowflake, GitLab And HubSpot Up 6%

Tiger Newspress
·
May 29

Tempus AI expects 25% top-line growth over next 3 years

TIPRANKS
·
May 29

Tempus AI reiterates FY26 revenue view of $1.59B-$1.6B, consensus $1.59B

TIPRANKS
·
May 29

Tempus AI announces initial results from Multimodal Foundation Model efforts

TIPRANKS
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune

Reuters
·
May 29

Tempus AI posts investor day presentation on AI-driven diagnostics, precision-medicine data platform

Reuters
·
May 29

Sector Update: Healthcare

MT Newswires Live
·
May 29

BUZZ-Tempus AI rises after securing FDA approval for tumor test

Reuters
·
May 29

Tempus AI Shares up 7.3% Premarket After FDA Approves Its Xt Cdx Test for Genetic Profiling of Tumors

THOMSON REUTERS
·
May 29

Movement Alert|Tempus AI Rises 5.77% in Pre-Market Trading, Oncology Xt Companion Diagnostic Product Receives FDA Approval

Market Focus
·
May 29

Stock Track | Tempus AI Soars 5.05% Pre-Market on FDA Approval for Tumor Diagnostic

Stock Track
·
May 29

Tempus wins FDA approval for tumor-only label on xT CDx genomic profiling test

Reuters
·
May 29